Clinical trial
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
NCT00353080 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00353080 |
|---|---|
| Title | Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women |
| Official title | A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal) |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | risedronate (HMR4003) |
| Enrollment | 171 |
| Start date | Dec 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jul 17, 2006 |
| Last update posted | Dec 15, 2009 |
| Countries | Finland, Netherlands, Norway, Spain, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: